Drugs Made In America Acquisition Corp. Ordinary Shares
$10.61
+0.094%Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
High confidenceValuation multiple is elevated (P/E 55.8).
Valuation inputs: P/E 55.8, earnings yield +1.8%, momentum +0.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE +2.5%, ROIC -1.2%).
Profitability stack: net margin 0.0%, ROE +2.5%, ROIC -1.2%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +3.0%, momentum +0.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Drugs Made In America Acquisition Corp. Ordinary Shares Market vs Earnings Trajectory
Loading price and EPS data...
Drugs Made In America Acquisition Corp. Ordinary Shares Fair Value Envelope
No Revenue Data
DMAA has not reported any revenue values in the available annual periods.
Drugs Made In America Acquisition Corp. Ordinary Shares Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
DMAA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
DMAA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
DMAA has not reported any net profit margin values in the available annual periods.
Drugs Made In America Acquisition Corp. Ordinary Shares Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.
Drugs Made In America Acquisition Corp. Ordinary Shares Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Warning: Liquidity concerns. Current assets may not be sufficient to cover short-term obligations.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Negative working capital indicates short-term liabilities exceed short-term assets—potential liquidity stress.
Asset Composition
Capital-intensive business with significant long-term investments in property, equipment, or intangibles.
Financial Health Insight
Conservative with tight liquidity: Low debt is positive, but current ratio warrants attention. Consider whether the company is efficiently deploying its equity capital.
Drugs Made In America Acquisition Corp. Ordinary Shares Street Expectations Map
No Target Data
No analyst price targets available for dmaa.
Drugs Made In America Acquisition Corp. Ordinary Shares Insider Positioning
During the last 12 months, there has been no insider trading activity reported for DMAA.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.
Insider Participation
No insider trading activity reported from any insiders in the past year.
No Dividend Yield Data
DMAA has not reported any dividend yield values in the available annual periods.
dmaa Dividend History
Learning Layer
Related Guides
Build conviction on DMAA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.